{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:16:09Z","timestamp":1793643369412,"version":"4.5.1"},"reference-count":53,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The anti-CD20 mAb rituximab is central to the treatment of B-cell malignancies, but resistance remains a significant problem. We recently reported that resistance could be explained, in part, by internalization of rituximab (type I anti-CD20) from the surface of certain B-cell malignancies, thus limiting engagement of natural effectors and increasing mAb consumption. Internalization of rituximab was most evident in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), but the extent of internalization was heterogeneous within each disease. Here, we show that the inhibitory Fc\u03b3RIIb on target B cells promotes this process and is largely responsible for the observed heterogeneity across a range of B-cell malignancies. Internalization correlated strongly with Fc\u03b3RIIb expression on normal and malignant B cells, and resulted in reduced macrophage phagocytosis of mAb-coated targets. Furthermore, transfection of Fc\u03b3RIIb into Fc\u03b3RIIb negative Ramos cells increased internalization of rituximab in a dose-dependent manner. Target-cell Fc\u03b3RIIb promoted rituximab internalization in a cis fashion and was independent of Fc\u03b3RIIb on neighboring cells. It became phosphorylated and internalized along with CD20:anti-CD20 complexes before lysosomal degradation. In MCL patients, high Fc\u03b3RIIb expression predicted less durable responses after rituximab-containing regimens. Therefore, target-cell Fc\u03b3RIIb provides a potential biomarker of response to type I anti-CD20 mAb.<\/jats:p>","DOI":"10.1182\/blood-2011-01-330357","type":"journal-article","created":{"date-parts":[[2011,7,19]],"date-time":"2011-07-19T00:35:21Z","timestamp":1311035721000},"page":"2530-2540","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":251,"title":["Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy"],"prefix":"10.1182","volume":"118","author":[{"given":"Sean H.","family":"Lim","sequence":"first","affiliation":[{"name":"Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Vaughan","sequence":"additional","affiliation":[{"name":"Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Ashton-Key","sequence":"additional","affiliation":[{"name":"Cancer Research UK Experimental Cancer Medicine Centre, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily L.","family":"Williams","sequence":"additional","affiliation":[{"name":"Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra V.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. T. Claude","family":"Chan","sequence":"additional","affiliation":[{"name":"Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Beers","sequence":"additional","affiliation":[{"name":"Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth R.","family":"French","sequence":"additional","affiliation":[{"name":"Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Cox","sequence":"additional","affiliation":[{"name":"Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Davies","sequence":"additional","affiliation":[{"name":"Cancer Research UK Experimental Cancer Medicine Centre, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Potter","sequence":"additional","affiliation":[{"name":"Cancer Research UK Experimental Cancer Medicine Centre, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ian","family":"Mockridge","sequence":"additional","affiliation":[{"name":"Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Oscier","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W. M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Cancer Research UK Experimental Cancer Medicine Centre, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Cragg","sequence":"additional","affiliation":[{"name":"Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Glennie","sequence":"additional","affiliation":[{"name":"Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2019111809134614400_B1","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111809134614400_B2","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111809134614400_B3","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"28","key":"2019111809134614400_B4","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111809134614400_B5","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9747","key":"2019111809134614400_B6","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"2019111809134614400_B7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/10428190902878471","article-title":"Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention.","volume":"50","author":"Stolz","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111809134614400_B8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives.","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"issue":"17","key":"2019111809134614400_B9","first-page":"5480","article-title":"CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.","volume":"63","author":"Chan","year":"2003","journal-title":"Cancer Res"},{"issue":"7","key":"2019111809134614400_B10","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","article-title":"Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.","volume":"103","author":"Cragg","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2019111809134614400_B11","first-page":"2143","article-title":"Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.","volume":"119","author":"Ivanov","year":"2009","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111809134614400_B12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"issue":"12","key":"2019111809134614400_B13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"issue":"2","key":"2019111809134614400_B14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.coi.2007.01.005","article-title":"Antibodies, Fc receptors and cancer.","volume":"19","author":"Nimmerjahn","year":"2007","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"2019111809134614400_B15","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood-2008-04-149161","article-title":"Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.","volume":"112","author":"Beers","year":"2008","journal-title":"Blood"},{"issue":"21","key":"2019111809134614400_B16","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111809134614400_B17","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct- and immune effector cell-mediated B-cell cytotoxicity.","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111809134614400_B18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses.","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2019111809134614400_B19","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/sj.leu.2403536","article-title":"FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).","volume":"18","author":"Camilleri-Broet","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"2019111809134614400_B20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/10428190902829441","article-title":"Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab.","volume":"50","author":"Weng","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111809134614400_B21","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1084\/jem.170.4.1369","article-title":"Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes.","volume":"170","author":"Brooks","year":"1989","journal-title":"J Exp Med"},{"issue":"5","key":"2019111809134614400_B22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0161-5890(93)90113-P","article-title":"Differential expression of Fc gamma RIIA, Fc gamma RIIB and Fc gamma RIIC in hematopoietic cells: analysis of transcripts.","volume":"30","author":"Cassel","year":"1993","journal-title":"Mol Immunol"},{"issue":"2","key":"2019111809134614400_B23","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4049\/jimmunol.152.2.574","article-title":"Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes.","volume":"152","author":"Van Den Herik-Oudijk","year":"1994","journal-title":"J Immunol"},{"issue":"2","key":"2019111809134614400_B24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0092-8674(89)90846-5","article-title":"Fc receptor isoforms exhibit distinct abilities for coated pit localization as a result of cytoplasmic domain heterogeneity.","volume":"58","author":"Miettinen","year":"1989","journal-title":"Cell"},{"issue":"48","key":"2019111809134614400_B25","doi-asserted-by":"crossref","first-page":"30636","DOI":"10.1016\/S0021-9258(18)43861-6","article-title":"Tyrosine-containing sequence motifs of the human immunoglobulin G receptors FcRIIb1 and FcRIIb2 essential for endocytosis and regulation of calcium flux in B cells.","volume":"269","author":"Budde","year":"1994","journal-title":"J Biol Chem"},{"issue":"25","key":"2019111809134614400_B26","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies.","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"issue":"25","key":"2019111809134614400_B27","doi-asserted-by":"crossref","first-page":"16971","DOI":"10.1074\/jbc.M708459200","article-title":"Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.","volume":"283","author":"Walshe","year":"2008","journal-title":"J Biol Chem"},{"issue":"11","key":"2019111809134614400_B28","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/0161-5890(91)90011-8","article-title":"Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab\u2032)2 derivative for recruitment of cytotoxic effectors.","volume":"28","author":"Greenman","year":"1991","journal-title":"Mol Immunol"},{"issue":"7","key":"2019111809134614400_B29","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.4049\/jimmunol.139.7.2367","article-title":"Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.","volume":"139","author":"Glennie","year":"1987","journal-title":"J Immunol"},{"issue":"6","key":"2019111809134614400_B30","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.4049\/jimmunol.161.6.3176","article-title":"Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.","volume":"161","author":"Tutt","year":"1998","journal-title":"J Immunol"},{"issue":"12","key":"2019111809134614400_B31","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","article-title":"Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.","volume":"15","author":"Austin","year":"2004","journal-title":"Mol Biol Cell"},{"issue":"12","key":"2019111809134614400_B32","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"issue":"18","key":"2019111809134614400_B33","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.","volume":"348","author":"Crespo","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111809134614400_B34","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"1","key":"2019111809134614400_B35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V98.1.181","article-title":"CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.","volume":"98","author":"Ibrahim","year":"2001","journal-title":"Blood"},{"issue":"6","key":"2019111809134614400_B36","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"4","key":"2019111809134614400_B37","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.","volume":"100","author":"Krober","year":"2002","journal-title":"Blood"},{"issue":"27","key":"2019111809134614400_B38","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1074\/jbc.M800784200","article-title":"CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins.","volume":"283","author":"Polyak","year":"2008","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111809134614400_B39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V43.6.789.789","article-title":"Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies. I. Detection and quantitation of light chain determinants.","volume":"43","author":"Ternynck","year":"1974","journal-title":"Blood"},{"issue":"1\u20133","key":"2019111809134614400_B40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0168-3659(02)00352-8","article-title":"Cytoplasmic delivery and nuclear targeting of synthetic macromolecules.","volume":"87","author":"Jensen","year":"2003","journal-title":"J Control Release"},{"issue":"2","key":"2019111809134614400_B41","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111809134614400_B42","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111809134614400_B43","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies.","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111809134614400_B44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2141.2003.04737.x","article-title":"FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas.","volume":"124","author":"Camilleri-Broet","year":"2004","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111809134614400_B45","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"4","key":"2019111809134614400_B46","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.","volume":"100","author":"Krober","year":"2002","journal-title":"Blood"},{"issue":"27","key":"2019111809134614400_B47","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1074\/jbc.M800784200","article-title":"CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins.","volume":"283","author":"Polyak","year":"2008","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111809134614400_B48","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V43.6.789.789","article-title":"Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies. I. Detection and quantitation of light chain determinants.","volume":"43","author":"Ternynck","year":"1974","journal-title":"Blood"},{"issue":"1\u20133","key":"2019111809134614400_B49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0168-3659(02)00352-8","article-title":"Cytoplasmic delivery and nuclear targeting of synthetic macromolecules.","volume":"87","author":"Jensen","year":"2003","journal-title":"J Control Release"},{"issue":"2","key":"2019111809134614400_B50","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111809134614400_B51","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111809134614400_B52","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies.","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111809134614400_B53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2141.2003.04737.x","article-title":"FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas.","volume":"124","author":"Camilleri-Broet","year":"2004","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/9\/2530\/1348099\/zh803511002530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/9\/2530\/1348099\/zh803511002530.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T05:50:52Z","timestamp":1686203452000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/9\/2530\/29477\/Fc-gamma-receptor-IIb-on-target-B-cells-promotes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,1]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-01-330357","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,1]]}}}